Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Head Movement Is More Important Than Gender In Nonverbal Communication, Psychologists Find
It is well known that people use head motion during conversation to convey a range of meanings and emotions, and that women use more active head motion when conversing with each other than men use when they talk with each other.
generic viagra online
New Data Shows Requip-Modutab Improves Nocturnal Symptoms In Patients With Advanced Parkinson's Disease
New data presented at the 13th International Congress of Parkinson"s Disease and Movement Disorders show that Requip-Modutab* (ropinirole prolonged release tablets) improves nocturnal symptoms experienced by patients with advanced Parkinson"s disease (PD).[i] The data showed that patients with more significant nocturnal symptoms had a greater improvement with Requip-Modutab, when used as an adjunct to levodopa (L-dopa), versus placebo. These data indicate that once-daily Requip-Modutab remains effective in treating PD symptoms over the night as well as during the day and provides benefit to those in most need. Sleep disturbances, a key element of nocturnal symptoms, are one of the most common non-motor complications of PD and can affect up to 98% of patients.[ii]
News of the day
Versartis Publishes Preclinical Abstracts For Two Product Candidates At 2009 American Diabetes Association Scientific Sessions
Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting beginning today in New Orleans.
Oncology

Afinitor(R) Phase II Data Show Positive Results For Patients With Multiple Types Of Lymphoma, Leading To Phase III Trial

from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group"s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. References 1. Thomas E. Witzig et al. A Phase II Trial of the Oral mTor Inhibitor Everolimus in Relapsed Non-Hodgkin"s Lymphoma (NHL) and Hodgkin"s Disease (HD). EHA 14th Congress. Berlin, Germany 2. National Cancer Institute. General Information about Non-Hodgkin Lymphoma. 3. National Cancer Institute. What You Need to Know About Non-Hodgkin"s Lymphoma. What is Non-Hodgkin"s Lymphoma? 4. National Cancer Institute. General Information on Non-Hodgkin"s. 5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin"s Lymphoma. 6. X Zhang et al. Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning. BMC Cancer 2007, 7:235 7. American Cancer Society. What Is Hodgkin"s Disease? 8. National Cancer Institute. General Information About Adult Non-Hodgkin"sLymphoma. 9. D. Max Parkin, MD et al. Global Cancer Statistics 2002. American Cancer Society. Novartis

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009